- Home
- NVCT vs BDN Comparison
NVCT vs BDN Comparison
Compare NVCT & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | BDN |
|---|---|---|
| Founded | 2020 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.7M | 554.5M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NVCT | BDN |
|---|---|---|
| Price | $24.19 | $3.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $3.50 |
| AVG Volume (30 Days) | 184.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 10.67% |
| EPS Growth | N/A | ★ 9.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $484,454,000.00 |
| Revenue This Year | N/A | $12.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.55 | $2.47 |
| 52 Week High | $29.28 | $4.63 |
Technical Indicators
Market Signals| Indicator | NVCT | BDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 51.56 |
| Support Level | $17.98 | $2.90 |
| Resistance Level | $25.94 | $3.15 |
| Average True Range (ATR) | 1.60 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 76.04 | 44.81 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About BDN Brandywine Realty Trust
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.